|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-.--% | - |
| Fiscal Period: September | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
Revenues | 359M | 364M | 429M | 470M |
Total Revenues | 359M | 364M | 429M | 470M |
Cost of Goods Sold, Total | 144M | 148M | 161M | 176M |
Gross Profit | 215M | 216M | 268M | 294M |
Selling General & Admin Expenses, Total | 146M | 165M | 184M | 193M |
R&D Expenses | 53.68M | 61.11M | 75.03M | 86.1M |
Other Operating Expenses | -22.01M | -14.96M | -14.55M | -9.2M |
Other Operating Expenses, Total | 178M | 211M | 245M | 270M |
Operating Income | 37.22M | 5.02M | 23.34M | 23.53M |
Interest Expense, Total | -3.67M | -5.31M | -6.37M | -10.56M |
Interest And Investment Income | 96K | 1.32M | 557K | 703K |
Net Interest Expenses | -3.58M | -3.99M | -5.81M | -9.86M |
Income (Loss) On Equity Invest. | 160K | 5.21M | -307K | -1.69M |
Currency Exchange Gains (Loss) | 122K | -2.33M | -5.1M | -8.3M |
Other Non Operating Income (Expenses) | - | - | -2.9M | -1.95M |
EBT, Excl. Unusual Items | 33.92M | 3.91M | 9.23M | 1.73M |
Impairment of Goodwill | - | - | -5.13M | -10.73M |
Other Unusual Items | 306K | 235K | - | 3.06M |
EBT, Incl. Unusual Items | 34.23M | 4.14M | 4.1M | -5.93M |
Income Tax Expense | 11.88M | 851K | 14.73M | 7.5M |
Earnings From Continuing Operations | 22.35M | 3.29M | -10.64M | -13.43M |
Net Income to Company | 22.35M | 3.29M | -10.64M | -13.43M |
Minority Interest | - | -98K | -87K | -625K |
Net Income - (IS) | 22.35M | 3.2M | -10.72M | -14.06M |
Net Income to Common Incl Extra Items | 22.35M | 3.2M | -10.72M | -14.06M |
Net Income to Common Excl. Extra Items | 22.35M | 3.2M | -10.72M | -14.06M |
Per Share Items | ||||
Net EPS - Basic | 1.18 | 0.17 | -0.57 | -0.75 |
Basic EPS - Continuing Operations | 1.18 | 0.17 | -0.57 | -0.75 |
Basic Weighted Average Shares Outstanding | 18.86M | 18.86M | 18.86M | 18.86M |
Net EPS - Diluted | 1.18 | 0.17 | -0.57 | -0.75 |
Diluted EPS - Continuing Operations | 1.18 | 0.17 | -0.57 | -0.75 |
Diluted Weighted Average Shares Outstanding | 18.86M | 18.86M | 18.86M | 18.86M |
Normalized Basic EPS | 1.12 | 0.12 | 0.3 | 0.02 |
Normalized Diluted EPS | 1.12 | 0.12 | 0.3 | 0.02 |
Dividend Per Share | 0.27 | 0.27 | - | - |
Payout Ratio | 18.57 | 159.36 | - | - |
Supplemental Items | ||||
EBITDA | 47.86M | 17.2M | 36.98M | 36.49M |
EBITA | 40.32M | 8.18M | 27.26M | 26.65M |
EBIT | 37.22M | 5.02M | 23.34M | 23.53M |
EBITDAR | 48.34M | 17.33M | 37.21M | 36.69M |
Effective Tax Rate - (Ratio) | 34.7 | 20.53 | 359.58 | -126.39 |
Normalized Net Income | 21.2M | 2.35M | 5.68M | 458K |
Interest on Long-Term Debt | 794K | 798K | 779K | 669K |
Non-Cash Pension Expense | 0 | 0 | 0 | -2K |
Supplemental Operating Expense Items | ||||
Research And Development Expense From Footnotes | 53.74M | 62.77M | 75.03M | 86.1M |
Net Rental Expense, Total | 480K | 124K | 231K | 205K |
Imputed Operating Lease Interest Expense | - | 32.08K | 55.5K | 65.75K |
Imputed Operating Lease Depreciation | - | 91.92K | 175K | 139K |
- Stock Market
- Stocks
- BNLB Stock
- Financials Brainlab SE
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















